Broadfin Capital’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Broadfin Capital’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-609,083	Closed	-$6.39M	–	78
2016 Q1	$6.39M	Hold	609,083	–	–	0.62%	43
2015 Q4	$18M	Hold	609,083	–	–	1.11%	22
2015 Q3	$19.2M	Buy	609,083 +101,490	+20%	+$4.86M	1.07%	18
2015 Q2	$30M	Buy	507,593 +290,760	+134%	+$20.5M	1.61%	13
2015 Q1	$23.2M	Sell	216,833 -88,167	-29%	-$8.4M	1.81%	12
2014 Q4	$28.6M	Sell	305,000 -45,000	-13%	-$4.29M	2.49%	10
2014 Q3	$26.9M	Hold	350,000	–	–	2.82%	10
2014 Q2	$25.1M	Hold	350,000	–	–	2.45%	13
2014 Q1	$15M	Buy	+350,000	New	+$11.6M	1.45%	24

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Broadfin Capital's PTX Position: Q2 2016 in Review

Broadfin Capital sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 609,083 shares — an estimated $6.39M sold.

Broadfin Capital first reported a position in PTX in Q1 2014 and held it in 9 quarters. The position peaked at $30M in Q2 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

Broadfin Capital reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
Broadfin Capital sold 609,083 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $6.39M.
Broadfin Capital first reported a position in Pernix Therapeutics Holdings, Inc. in Q1 2014 and held it in 9 quarters.
Broadfin Capital's Pernix Therapeutics Holdings, Inc. position peaked at $30M in Q2 2015.
56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.